Kendle’s income and cancellations surge

By Nick Taylor

- Last updated on GMT

Related tags Contract research organisation Contract research organization

Kendle International has posted impressive third quarter results, despite seeing a dramatic increase in the number of contract cancellations during the period.

The contract research organisation (CRO) recorded an operating income of $15.9m for the third quarter, up from $14.2m in the corresponding period of 2007, but contract cancellations rose by over 500 per cent to $38m.

This was offset by a rise of 21 per cent in net business awarded in the quarter to $212m, which has given Kendle the belief that its successful 2008 can continue into next year.

Candace Kendle, CEO of Kendle, said: "Our impressive results for the quarter are a testament to the strength of our late stage markets, the value of our business model and the expertise and determination of our associates worldwide​.

Coupled with our broad therapeutic and geographic reach, we believe we are well positioned to achieve our strategic growth initiatives and to meet our customers emerging outsourcing needs​."

In recent years Kendle’s management has attempted to expand its offering into new geographic regions and therapeutic areas, which appears to have been a successful policy.

This should equip Kendle to prosper in the current financial climate, in which more companies may be looking to outsource but also more may cancel contracts as they attempt to balance the books.

Kendle’s successful third quarter is the continuation of a good 2008, in which total business authorisations have reached $1bn, up by 16 per cent on the whole of 2007.

Related news

Show more

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Automated metadata management in clinical trials

Automated metadata management in clinical trials

Content provided by Formedix | 01-Aug-2023 | White Paper

When it comes to efficient clinical study build, content is king. Most importantly: metadata content. In this blog, we explore the role of metadata in...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Related suppliers

Follow us

Products

View more

Webinars